By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Anika Therapeutics 

32 Wiggins Avenue

Bedford  Massachusetts  01730   U.S.A.
Phone: 781-457-9000 Fax: 781-935-4120

Anika Therapeutics is a pioneer in developing therapeutic products for tissue protection, healing and repair. These products are based on hyaluronic acid (HA), a naturally occurring polymer found throughout the body. HA enhances joint function and coats, protects, cushions and lubricates soft tissues. HA also is present in the skin, where it supports skin structure and elasticity. With more than 20 years of experience in HA technology, Anika is recognized worldwide as a provider of premium HA products that are effective, safe and long-lasting.

Anika manufactures and distributes a diverse portfolio of HA-based products that cover a broad range of therapeutic applications. These products include ORTHOVISC®, ORTHOVISC® mini, and MONOVISC™ used in the treatment of osteoarthritis; HYVISC® used in the treatment of equine osteoarthritis; the ELEVESS™ family of cosmetic dermatology products for facial wrinkles, scar remediation and lip augmentation; AMVISC®, AMVISC® Plus, STAARVISC™ II, and OPTIVISC™ injectable viscoelastic HA products for ophthalmic surgery; INCERT®, an HA-based anti-adhesive for surgical applications; and next-generation products for joint health and aesthetic dermatology based on the Company's proprietary, chemically modified HA.

Key Statistics

Ownership: Public

Web Site: Anika Therapeutics
Symbol: ANIK


Company News
Anika Therapeutics (ANIK) Announces First Patient Enrolled in FastTRACK Phase III HYALOFAST Study 12/30/2015 9:58:34 AM
Anika Therapeutics (ANIK) Announces Decision To Proceed With CINGAL Premarket Review Through FDA’s Center For Drug Evaluation And Research 12/10/2015 11:09:09 AM
Anika Therapeutics (ANIK) To Present At The 27th Annual Piper Jaffray Healthcare Conference On December 1 11/19/2015 10:07:30 AM
Anika Therapeutics (ANIK) Announces Health Canada Approval Of CINGAL For The Treatment Of Pain Associated With Osteoarthritis Of The Knee 11/3/2015 11:07:08 AM
Anika Therapeutics (ANIK) Appoints Richard Hague To Role Of Chief Commercial Officer 10/29/2015 11:55:33 AM
Anika Therapeutics (ANIK) Reports Robust Financial Performance And Continued Progress On Key Fronts In Third Quarter Of 2015 10/29/2015 11:11:07 AM
Anika Therapeutics (ANIK) To Issue Third-Quarter 2015 Financial Results And Business Highlights On Wednesday, October 28 10/14/2015 4:07:01 PM
Anika Therapeutics (ANIK) Delivers Solid Second Quarter 2015 Financial Results And Continued Pipeline Progress 7/30/2015 1:03:10 PM
Anika Therapeutics (ANIK) To Issue Second Quarter 2015 Financial Results And Business Highlights On Wednesday, July 29 7/15/2015 10:37:38 AM
Anika Therapeutics (ANIK) Announces Positive Results From Follow-Up Study Evaluating Safety Of A Repeat Injection Of CINGAL For Treatment Of Osteoarthritis Of The Knee 7/9/2015 7:38:24 AM